IPSEF News and Press, Ipsen From 02/13/25

FY 2024 total sales growth of 9.9% at CER 1 , or 8.7% as reported, with growth driven by strong performance across all therapeutic areas, including a 67.4% increase in the Rare Diseases portfolio, 9.2% in Neuroscience, and 7.3% in Oncology; Somatuline ® (lanreotide) sales grew by 5.6...

2025-01-08 11:05:43 ET Summary The biotech industry is primed for increased M&A activity due to low valuations and big pharma's need to offset patent losses. Mirum Pharmaceuticals, with three approved drugs and a strong pipeline, is a possible prime takeover candidate with sig...

2025-01-07 11:31:19 ET Summary Day One Biopharmaceuticals focuses on pediatric cancer treatments, with a promising pipeline including tovorafenib and other targeted therapies. The stock has experienced a bearish trend but has significant upside potential, with Wall Street targetin...